Compare Stocks: FGEN, TNYA, INO, and BMEA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMEA Biomea Fusion	$1.85 -4.1%	$1.43	$0.87 ▼ $2.99	$139.89M	-0.23	1.95 million shs	2.50 million shs
FGEN FibroGen	$9.77 +8.3%	$9.21	$4.85 ▼ $12.60	$39.57M	0.77	40,794 shs	31,125 shs
INO Inovio Pharmaceuticals	$1.32 -7.0%	$1.09	$0.56 ▼ $2.82	$146.82M	1.63	4.74 million shs	2.69 million shs
TNYA Tenaya Therapeutics	$0.66 -0.5%	$0.75	$0.53 ▼ $2.35	$148.75M	2.77	1.73 million shs	1.18 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMEA Biomea Fusion	-4.15%	-4.39%	+45.67%	+55.46%	-0.54%
FGEN FibroGen	0.00%	0.00%	0.00%	0.00%	-14.90%
INO Inovio Pharmaceuticals	-7.04%	-2.94%	+79.25%	+20.00%	-52.00%
TNYA Tenaya Therapeutics	-0.51%	-5.62%	-10.50%	-8.31%	-49.23%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMEA Biomea Fusion	$1.85 -4.1%	$1.43	$0.87 ▼ $2.99	$139.89M	-0.23	1.95 million shs	2.50 million shs
FGEN FibroGen	$9.77 +8.3%	$9.21	$4.85 ▼ $12.60	$39.57M	0.77	40,794 shs	31,125 shs
INO Inovio Pharmaceuticals	$1.32 -7.0%	$1.09	$0.56 ▼ $2.82	$146.82M	1.63	4.74 million shs	2.69 million shs
TNYA Tenaya Therapeutics	$0.66 -0.5%	$0.75	$0.53 ▼ $2.35	$148.75M	2.77	1.73 million shs	1.18 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMEA Biomea Fusion	-4.15%	-4.39%	+45.67%	+55.46%	-0.54%
FGEN FibroGen	0.00%	0.00%	0.00%	0.00%	-14.90%
INO Inovio Pharmaceuticals	-7.04%	-2.94%	+79.25%	+20.00%	-52.00%
TNYA Tenaya Therapeutics	-0.51%	-5.62%	-10.50%	-8.31%	-49.23%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMEA Biomea Fusion	2.67	Moderate Buy	$9.00	386.49% Upside
FGEN FibroGen	2.00	Hold	$43.00	340.12% Upside
INO Inovio Pharmaceuticals	2.75	Moderate Buy	$3.17	139.90% Upside
TNYA Tenaya Therapeutics	2.86	Moderate Buy	$4.00	506.06% Upside

Current Analyst Ratings Breakdown

Latest FGEN, TNYA, INO, and BMEA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	BMEA Biomea Fusion	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/13/2026	INO Inovio Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	INO Inovio Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/13/2026	INO Inovio Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Positive	$1.80 ➝ $3.00
8/12/2026	INO Inovio Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/3/2026	INO Inovio Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$4.00
7/29/2026	INO Inovio Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/28/2026	TNYA Tenaya Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/2/2026	TNYA Tenaya Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/1/2026	BMEA Biomea Fusion	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/1/2026	INO Inovio Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	$0.42 per share	N/A
FGEN FibroGen	$29.62M	1.34	N/A	N/A	($50.89) per share	-0.19
INO Inovio Pharmaceuticals	$60K	2,274.80	N/A	N/A	$0.36 per share	3.67
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	$0.57 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMEA Biomea Fusion	-$61.80M	-$0.29	N/A	N/A	N/A	N/A	-253.73%	-97.91%	11/3/2026 (Estimated)
FGEN FibroGen	-$47.58M	$53.48	0.18	N/A	N/A	2,598.55%	N/A	-26.27%	N/A
INO Inovio Pharmaceuticals	-$84.95M	-$0.91	N/A	N/A	N/A	N/A	-669.94%	-73.97%	11/10/2026 (Estimated)
TNYA Tenaya Therapeutics	-$90.60M	-$0.53	N/A	N/A	N/A	N/A	-83.75%	-66.53%	11/11/2026 (Estimated)

Latest FGEN, TNYA, INO, and BMEA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	INO Inovio Pharmaceuticals	-$0.2167	-$0.07	+$0.1467	-$0.07	$0.53 million	N/A
8/6/2026	Q2 2026	BMEA Biomea Fusion	-$0.2235	-$0.12	+$0.1035	-$0.12	N/A	N/A
8/5/2026	Q2 2026	TNYA Tenaya Therapeutics	-$0.0683	-$0.20	-$0.1317	-$0.20	$10.00 million	$1.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	N/A
FGEN FibroGen	N/A	N/A	N/A	N/A	N/A
INO Inovio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMEA Biomea Fusion	N/A	3.47	3.47
FGEN FibroGen	N/A	3.71	3.60
INO Inovio Pharmaceuticals	N/A	1.00	1.00
TNYA Tenaya Therapeutics	N/A	4.52	4.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMEA Biomea Fusion	96.72%
FGEN FibroGen	72.71%
INO Inovio Pharmaceuticals	26.79%
TNYA Tenaya Therapeutics	90.54%

Insider Ownership

Company	Insider Ownership
BMEA Biomea Fusion	10.60%
FGEN FibroGen	3.07%
INO Inovio Pharmaceuticals	1.70%
TNYA Tenaya Therapeutics	2.53%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMEA Biomea Fusion	50	72.48 million	64.80 million	Optionable
FGEN FibroGen	570	4.05 million	3.92 million	Optionable
INO Inovio Pharmaceuticals	320	103.40 million	101.64 million	Optionable
TNYA Tenaya Therapeutics	110	224.23 million	218.56 million	Optionable

FGEN, TNYA, INO, and BMEA Headlines

Recent News About These Companies

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $4.00 Average PT from Analysts

4 hours ago | americanbankingnews.com

BlackRock Inc. Acquires New Stake in Tenaya Therapeutics, Inc. $TNYA

September 6, 2026 | marketbeat.com

Tenaya Therapeutics (NASDAQ:TNYA) Upgraded at Wall Street Zen

September 6, 2026 | americanbankingnews.com

Wall Street Zen Upgrades Tenaya Therapeutics (NASDAQ:TNYA) to Sell

September 6, 2026 | marketbeat.com

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

September 5, 2026 | marketbeat.com

Tenaya Therapeutics to Participate in Upcoming September Investor Conferences

September 3, 2026 | globenewswire.com

Tenaya Therapeutics (NASDAQ:TNYA) Cut to Strong Sell at Wall Street Zen

August 29, 2026 | marketbeat.com

1,555,500 Shares in Tenaya Therapeutics, Inc. $TNYA Purchased by ADAR1 Capital Management LLC

August 26, 2026 | marketbeat.com

Empery Asset Management LP Takes $2.86 Billion Position in Tenaya Therapeutics, Inc. $TNYA

August 22, 2026 | marketbeat.com

Faraz Ali Sells 22,232 Shares of Tenaya Therapeutics (NASDAQ:TNYA) Stock

August 18, 2026 | insidertrades.com

Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301

August 18, 2026 | marketbeat.com

Tenaya Therapeutics (NASDAQ:TNYA) CEO Sells $15,784.72 in Stock

August 17, 2026 | marketbeat.com

GSA Capital Partners LLP Makes New $1.97 Million Investment in Tenaya Therapeutics, Inc. $TNYA

August 17, 2026 | marketbeat.com

Tenaya Therapeutics, Inc. (TNYA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

August 14, 2026 | seekingalpha.com

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Recommendation of "Moderate Buy" by Brokerages

August 11, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA) and Viridian Therapeutics (VRDN)

August 7, 2026 | theglobeandmail.com

Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 5, 2026 | globenewswire.com

Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

August 4, 2026 | globenewswire.com

Cours Tenaya Therapeutics, Inc.

July 29, 2026 | zonebourse.comZ

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

July 14, 2026 | globenewswire.com

Tenaya Therapeutics (TNYA) Slides to $0.86 as Bearish Pressure Tests Support - Order Block

July 13, 2026 | donanimhaber.comD

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

FGEN, TNYA, INO, and BMEA Company Descriptions

Biomea Fusion NASDAQ:BMEA

$1.85 -0.08 (-4.15%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$1.87 +0.02 (+1.30%)

As of 07:47 AM Eastern

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

FibroGen NASDAQ:FGEN

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Inovio Pharmaceuticals NASDAQ:INO

$1.32 -0.10 (-7.04%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$1.34 +0.02 (+1.89%)

As of 07:51 AM Eastern

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Tenaya Therapeutics NASDAQ:TNYA

$0.66 0.00 (-0.51%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$0.68 +0.02 (+2.27%)

As of 07:51 AM Eastern

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FGEN, TNYA, INO, and BMEA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FGEN, TNYA, INO, and BMEA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FGEN, TNYA, INO, and BMEA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

FGEN, TNYA, INO, and BMEA Company Descriptions

Biomea Fusion NASDAQ:BMEA

FibroGen NASDAQ:FGEN

Inovio Pharmaceuticals NASDAQ:INO

Tenaya Therapeutics NASDAQ:TNYA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FGEN, TNYA, INO, and BMEA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FGEN, TNYA, INO, and BMEA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FGEN, TNYA, INO, and BMEA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

FGEN, TNYA, INO, and BMEA Company Descriptions

Biomea Fusion NASDAQ:BMEA

FibroGen NASDAQ:FGEN

Inovio Pharmaceuticals NASDAQ:INO

Tenaya Therapeutics NASDAQ:TNYA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools